Pharmaceuticals : Misleading Promotion

PHARMACEUTICALS misleading data and suppression of clinical information by drug companies. These are some of the issues that must become part Misleading Promotion The recent court proceedings of the case against GlaxoSmithkline (GSK) in the US have reopened the debate and concerns over the use and acceptance of unpublished data in licensing applications. One outcome has been a change in the regulatory structure and process that ought to be of significance to regulatory authorities everywhere, especially where it is as yet to develop fully.